Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference56 articles.
1. Dougados M, Baeten D. Spondyloarthritis Lancet. 2011;377(9783):2127–37. https://doi.org/10.1016/s0140-6736(11)60071-8.
2. Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017;7(9):e015872. https://doi.org/10.1136/bmjopen-2017-015872.
3. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73. https://doi.org/10.1136/annrheumdis-2013-203582.
4. Wronski J, Fiedor P. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought? J Clin Pharmacol. 2019;59(4):445–62. https://doi.org/10.1002/jcph.1348.
5. Arends S, Brouwer E, Efde M, Veer E, Bootsma H, Wink F, et al. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2017;35(1):61–8.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献